Medical Policy Update for March 8, 2022
| Medical Guidelines | Reason for Update |
| IV Iron Replacement Therapy | Added pediatric Injectafer indication. |
| Interleukin-5 Antagonist | Added indication for Nucala of chronic rhinosinusitis with nasal polyposis with initial and continuation criteria for approval and updated dosing table/max units with new indication |
| Abatacept (Orencia®) | Added new indication of prophylaxis of acute graft vs host disease with corresponding criteria and dosing table updates. Updated maximum units to 1500. |
Blue Connect